The failure of Merck & Co. Inc.'s Phase III KEYNOTE-061 study of Keytruda in second-line advanced gastric cancer may wind up having little commercial downside, as there will be no change in labeling.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?